Obsidian Therapeutics is presenting today at the #SITC Annual Meeting Poster Session! Check out abstract 444: Potential feasibility of core needle biopsy tumor tissue procurement method for TIL cell therapy with OBX-115 in non-small cell lung cancer (NSCLC).
Obsidian Therapeutics
生物技术研究
Cambridge，MA 10,036 位关注者
At Obsidian, our vision is pioneering engineered cell & gene therapies to deliver transformative outcomes for patients.
关于我们
Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need. Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.
- 网站
-
https://www.obsidiantx.com
Obsidian Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，MA
- 类型
- 私人持股
- 创立
- 2015
地点
-
主要
获取路线
1030 Massachusetts Avenue
Suite 400
US，MA，Cambridge，02138
Obsidian Therapeutics员工
动态
-
Obsidian Therapeutics is presenting two posters today at the #SITC Annual Meeting Poster Session! Check out abstracts 462, Antigen-responsive promoters coupled with cytoDRiVE? technology provide tight spatiotemporal regulation for tumor-infiltrating lymphocytes (TIL) expressing membrane-bound IL12, and 457, Engineered tumor-infiltrating lymphocytes (TIL) with co-regulated membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) generate significant antitumor efficacy in fibrotic tumor models.
-
-
Today at #SITC, Obsidian is presenting two preclinical posters at the SITC Immune Engineering Workshop, which will be held from 3:10-5:00pm CT. Learn more here: https://lnkd.in/eEBaPCJP
-
-
The #SITC Communications Committee selected one of Obsidian’s abstracts to be presented at the SITC 2024 Annual Meeting Press Conference! Lead author Sean Smith will present the abstract to the media this afternoon. Be sure to check out the poster, which will be available during the Annual Meeting Poster Session on November 8.
-
-
Today at the #SITC TIL Symposium, our Chief Development Officer, Parameswaran Hari, will be presenting a talk titled, “Armoring Tumor-infiltrating Lymphocytes (TIL) with Membrane-bound IL15 Improves T-cell Phenotype and Enhances Persistence in Melanoma.” Also at the TIL Symposium, our Chief Executive Officer, Madan Jagasia, will be participating in a roundtable discussion during the SITC TIL Symposium. Check out the full schedule and other pre-conference activities here: https://lnkd.in/g2J7kjbB
-
-
Today Obsidian announced the publication of 3 abstracts for poster presentations at #SITC2024. Obsidian will share preclinical data supporting the potential of its cytoDRiVE platform to enable a more patient-centric, core needle biopsy tumor tissue procurement procedure for OBX-115 manufacturing in non-small cell lung cancer (NSCLC) and to potentially expand the therapeutic window and application of potent, immune-modulating cytokines for armored cell therapies. See more here: https://lnkd.in/efM9i6Py?
-
-
At Obsidian Therapeutics we believe that healthy relationships and high performing teams develop when we can be our whole selves.?We make time to connect, have fun, exercise our creativity, and get to know each other's stories and interests.?Below are just a few of our fall activities.?
-
-
Our CEO, Madan Jagasia, is participating in two events at the TIL Therapies Summit in Boston today: At 8:30am, Madan is featured in the Industry Leaders Fireside Chat, titled, “Challenges & Opportunities in Expanding Beyond Melanoma”, along with panelists from KSQ Therapeutics, GRIT Biotechnology & Iovance Biotherapeutics. ? Madan is also presenting on our TIL cell therapy, OBX-115, at 3:30 pm: “Improving Efficacy and Minimizing Safety Risks of TIL Cell Therapy by Rational Engineering of TIL” ? See more here: https://til-therapies.com/
-
-
Welcome to our most recent hires – we’re honored that you’ve chosen to join us, and excited about what we can achieve together!?? ??? #obsidianrocks?
-
-
On Friday morning, our Chief Development Officer, Parameswaran Hari, will be presenting at the CAR-TCR Summit Series in Boston. His talk is titled, “Armoring Tumor-infiltrating Lymphocytes (TIL) with Membrane-bound IL15 Improves T-cell Phenotype and Enhances Persistence in Melanoma.” Check it out here: https://lnkd.in/dcURYAy7
-